British Business Bank backs Apposite with GBP £100m

The British Business Bank has made a GBP £100 million commitment to Apposite Healthcare Growth I, its largest fund commitment to date.

The fund will back health technology companies, primarily in the UK, and is the bank's first commitment to Apposite Capital, a specialist healthcare and life sciences investor.

Apposite Healthcare Growth I will invest in companies across medical products, diagnostics, life sciences tools, digital health and pharmaceutical outsourcing services. The fund is intended to help address a shortage of scale-up capital for UK life sciences businesses as they reach a critical stage of growth.

The commitment also aligns with the state-backed investor's broader push to increase support for scale-ups. More than 60% of its venture and growth investment flows are directed toward scale-ups, alongside a goal of launching 10 new growth-stage funds over the next five years.

Cornerstone backing from the British Business Bank is intended to help fund managers reach a first close and raise capital at a greater scale. In this case, the GBP £100 million commitment gives Apposite's new fund a significant early anchor investor as it looks to back later-stage healthcare businesses.

Scale-up gap

The focus on life sciences reflects a longstanding funding challenge in the UK. The country has a strong base in research, early-stage company formation and scientific talent, but later-stage funding has often been harder to secure, particularly for businesses seeking to expand without turning to overseas investors or accepting an early sale.

The British Business Bank, which describes itself as the largest investor in UK venture and venture growth capital funds, has increasingly used larger commitments to support specialist managers in sectors with more pronounced financing gaps. Healthcare and life sciences are a particular concern because companies in these sectors often require more capital and longer development timelines than software or consumer technology businesses.

"The UK needs growth stage funding, and the Bank is stepping up to deliver this. Working with the UK's venture capital community, we are looking to support the creation of growth stage funds capable of writing significant cheques into the next generation of UK unicorns. To help these funds launch and ensure they have the size and firepower needed, we are writing larger cheques and signalling these commitments to institutional investors, with the intention it mobilises the private sector," Christine Hockley, Managing Director and Head of Commercial Equity Funds at the British Business Bank, said.

"The need for scale-up funding is especially pronounced in life sciences. However, there remains a shortage of later-stage funds, meaning that many promising life sciences companies cannot fulfil their potential in the UK and may embark on premature or sub-optimal exits. Apposite's new fund has a clear focus on growth stage investing in life sciences and will help convert world-leading UK science into global companies," said Mark Andrews, Investment Director, Funds, Life Sciences at the British Business Bank.

Health focus

Apposite has focused on healthcare and life sciences since its founding in 2006. The new fund adds a growth-stage vehicle to its investment platform, targeting businesses that have moved beyond the earliest phases and need larger sums to expand commercially.

According to details released alongside the commitment, the fund will target companies developing technologies and services designed to improve patient outcomes and access to healthcare. It will also look at businesses with the potential to expand internationally while remaining rooted in the UK.

For ministers, the deal supports a wider industrial policy focus on innovation-led growth. Healthcare technology and life sciences have featured prominently in government efforts to strengthen sectors where the UK already has a research base and a pipeline of emerging companies.

"We've committed to backing our most ambitious companies, ensuring the UK leads in innovation and competes globally," Peter Kyle, Secretary of State for Business and Trade, said.

"This record investment into Apposite Capital delivers on that promise by giving it the financial firepower to help the UK's most exciting healthcare tech firms scale, develop cutting-edge medical products and diagnostics, and improve healthcare right across the country."

Apposite said the backing would help it invest in growing businesses across the healthcare sector.

"The commitment from the British Business Bank will enable Apposite to continue its strong track record of supporting ambitious growing companies and investing in businesses that can achieve better healthcare for more people. Apposite Healthcare Growth I will back the next generation of UK healthcare technology leaders. The UK is home to an extraordinary depth of scientific research, entrepreneurial talent, and innovative companies, yet many businesses face a persistent gap in scale-up funding. This fund will bridge that gap, enabling high-potential companies to accelerate their growth, commercialise transformative technologies, improve health outcomes and support economic growth," Sam Gray, Managing Partner at Apposite Capital, said.